Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema

What Was Tested

Researchers studied Bradykinin and Icatibant in this randomized controlled trial publication.

Hereditary angioedema is characterized by recurrent attacks of angioedema of the skin, larynx, and gastrointestinal tract.

Bradykinin is the key mediator of symptoms.

Who Took Part

According to the abstract, 2, patients were involved.

The age groups tagged for this paper are adults, both men and women.

In two double-blind, randomized, multicenter trials, the researchers evaluated the effect of icatibant in patients with hereditary angioedema presenting with cutaneous or abdominal attacks.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and multicenter study.

Because people in this Bradykinin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Bradykinin study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Bradykinin group a baseline to be compared against.

Running at several centres spread the Bradykinin study over different clinics and patient groups.

What Was Measured

Hereditary angioedema is characterized by recurrent attacks of angioedema of the skin, larynx, and gastrointestinal tract.

The subject headings attached to it are Acute Disease, Angioedemas, Hereditary, Bradykinin, Bradykinin B2 Receptor Antagonists, Intention to Treat Analysis, Statistics, Nonparametric and Tranexamic Acid.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Bradykinin and Icatibant in 2, patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2010 (The New England journal of medicine), a journal based in United States.

More context: the Bradykinin compound page and the Icatibant compound page, all human trials.